Results 81 to 90 of about 5,019 (231)
VIEW, EarlyView.Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf +5 more
wiley +1 more source
Acta Crystallographica Section F, EarlyView.Structural and binding studies of the engineered lipocalin CL31d towards the chelate complexes of 11 different lanthanide and main‐group metal(III) ions, whose radioisotopes are useful for nuclear medicine, with a functionalized DTPA revealed a surprisingly broad tolerance towards varying ionic radii, thus enabling flexible radionuclide‐targeting ...
Alina Mirwald +2 more
wiley +1 more source
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells
Allergy, EarlyView.We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller +16 more
wiley +1 more source
Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies
CancersObjectives: Reduced expression of adhesion molecules in tumor vasculature can limit infiltration of effector T cells. To improve T cell adhesion to tumor endothelial cell (EC) antigens and enhance transendothelial migration, we developed bispecific, T-cell engaging antibodies (bsAb) that activate T cells after cross-linking with EC cell surface ...
Márcia Gonçalves +7 more
openaire +2 more sources
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Pharmacology & Therapeutics, 2018 Harnessing the power of the human immune system to treat cancer is the essence of immunotherapy. Monoclonal antibodies engage the innate immune system to destroy targeted cells. For the last 30years, antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity have been the main mechanisms of anti-tumor action of unconjugated ...
Z, Wu, N V, Cheung
openaire +3 more sources
Andrology, EarlyView.ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick +7 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos +4 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui +7 more
wiley +1 more source
Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
Antibody TherapeuticsAbstract T-cell engagers (TCEs) represent an emerging class of immunotherapies that harness T cells’ cytotoxic power to eliminate diseased cells—a transformative future therapeutic strategy. TCEs form immunological synapses to trigger potent immune responses, with proven efficacy in blood cancers; research expands their use to solid ...
Xiaoqiang Kang +3 more
openaire +3 more sources
British Journal of Haematology, EarlyView.Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo +14 more
wiley +1 more source